Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
FibroGen ( (FGEN) ) has issued an announcement.
On July 14, 2025, FibroGen amended its financing agreement with Morgan Stanley Tactical Value, reducing the minimum cash balance requirement from $22.5 million to $18.75 million. This adjustment may impact FibroGen’s financial flexibility and operational strategies, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (FGEN) stock is a Sell with a $0.60 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.
Spark’s Take on FGEN Stock
According to Spark, TipRanks’ AI Analyst, FGEN is a Neutral.
FibroGen’s stock score is primarily impacted by its challenging financial performance, with persistent losses and declining revenues. The earnings call provided some positive strategic developments, but the overall financial instability overshadows these advancements. Technical analysis and valuation also present concerns, contributing to a lower overall score.
To see Spark’s full report on FGEN stock, click here.
More about FibroGen
FibroGen operates in the biopharmaceutical industry, focusing on the development and commercialization of novel therapeutics to treat serious unmet medical needs.
Average Trading Volume: 42,468
Technical Sentiment Signal: Strong Sell
Current Market Cap: $28.9M
For a thorough assessment of FGEN stock, go to TipRanks’ Stock Analysis page.